This article has been corrected | View Correction

ArticlesFull Access

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

Search for more papers by this author

, M.D.,

Search for more papers by this author

, M.D.,

Madhukar Trivedi

Search for more papers by this author

, M.D.,

Kimberly Cooper

Search for more papers by this author

, M.S.,

Search for more papers by this author

, M.A.S.,

Search for more papers by this author

, Ph.D.,

Christine Mazzucco

Search for more papers by this author

, M.Sc.,

Search for more papers by this author

, M.D.,

Michael E. Thase

Search for more papers by this author

, M.D.,

Richard C. Shelton

Search for more papers by this author

, M.D.,

Patricio Molero

Search for more papers by this author

, M.D., Ph.D.,

Search for more papers by this author

, M.D., Ph.D.,

Search for more papers by this author

, M.D.,

Search for more papers by this author

, M.D.,

Wayne C. Drevets

Search for more papers by this author

, M.D.,

Jaskaran B. Singh

Search for more papers by this author

, M.D.

Published Online:21 May 2019https://doi.org/10.1176/appi.ajp.2019.19020172

Supplemental Material

• Correction: AJP_19020172_correction01.pdf

• Online supplement: appi.ajp.2019.19020172.ds001.pdf

Cited by
- Ketamine cystitis following ketamine therapy for treatment-resistant depression – case report
  2 January 2024 | BMC Psychiatry, Vol. 24, No. 1
- Effect of esketamine on the EC50 of remifentanil for blunting cardiovascular responses to endotracheal intubation in female patients under general anesthesia: a sequential allocation dose-finding study
  21 February 2024 | BMC Anesthesiology, Vol. 24, No. 1
- Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis
  Journal of Affective Disorders, Vol. 356
- Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
  Journal of Affective Disorders, Vol. 356
- Efficacy of Esketamine among patients with treatment resistant depression in a ‘real world' health-care setting in Israel
  Journal of Psychiatric Research, Vol. 174
- Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
  10 May 2024 | Drugs - Real World Outcomes, Vol. 15
- Immunotherapy for depression: Recent insights and future targets
  Pharmacology & Therapeutics, Vol. 257
- Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation – Clinical and safety results
  Journal of Psychiatric Research, Vol. 173
- Effects of the selective AMPA modulator NBI ‐1065845 on the pharmacokinetics of midazolam or ethinyl estradiol–levonorgestrel in healthy adults
  3 May 2024 | Clinical and Translational Science, Vol. 17, No. 5
- Efficacy and safety of esketamine for perioperative depression in patients undergoing elective surgery: A meta-analysis of randomized controlled trials
  Asian Journal of Psychiatry, Vol. 95
- Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
  29 April 2024 | Frontiers in Psychiatry, Vol. 15
- Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023
  25 April 2024 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 292
- ESKETAMINE
- Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
  17 April 2024 | Wiener klinische Wochenschrift, Vol. 48
- The efficacy of nasal administration of esketamine in patients having moderate-to-severe pain after preoperative CT-guided needle localization: a randomized, double-blind, placebo-controlled trial
  9 April 2024 | Frontiers in Medicine, Vol. 11
- A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review
  Journal of Affective Disorders, Vol. 350
- Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand
  1 April 2024 | Australian & New Zealand Journal of Psychiatry
- Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery–Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire
  1 April 2024 | CNS Spectrums, Vol. 25
- Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension
  25 March 2024 | Molecular Psychiatry, Vol. 163
- Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis
  8 March 2024 | Frontiers in Psychiatry, Vol. 15
- Perioperative Adjunctive Esketamine for Postpartum Depression Among Women Undergoing Elective Cesarean Delivery
  6 March 2024 | JAMA Network Open, Vol. 7, No. 3
- The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
  Journal of Affective Disorders, Vol. 348
- Exploring Novel Antidepressants Targeting G Protein-Coupled Receptors and Key Membrane Receptors Based on Molecular Structures
  22 February 2024 | Molecules, Vol. 29, No. 5
- Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances
  5 March 2024 | International Journal of Translational Medicine, Vol. 4, No. 1
- An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions
  Trends in Neurosciences, Vol. 47, No. 3
- Association between esketamine interventions and postpartum depression and analgesia following cesarean delivery: a systematic review and meta-analysis
  American Journal of Obstetrics & Gynecology MFM, Vol. 6, No. 3
- The proper anesthesia for an 81-year-old woman with respiratory dysfunction after COVID-19 infection undergoing total hysterectomy
  Asian Journal of Surgery, Vol. 166
- Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted: Clinical Experience from a Spanish Cohort of Expanded Use
  6 September 2023 | Clinical Psychopharmacology and Neuroscience, Vol. 22, No. 1
- Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials
  15 February 2024 | Frontiers in Psychiatry, Vol. 15
- Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis
  Journal of Affective Disorders, Vol. 346
- Efficacy and Safety of Antidiabetic Agents for Major Depressive Disorder and Bipolar Depression: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
  19 February 2024 | Journal of Clinical Medicine, Vol. 13, No. 4
- Opioid use disorder: current trends and potential treatments
  25 January 2024 | Frontiers in Public Health, Vol. 11
- Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety
  23 January 2024 | Frontiers in Psychiatry, Vol. 15
- Research progress on antidepressant effects and mechanisms of berberine
  22 January 2024 | Frontiers in Pharmacology, Vol. 15
- The efficacy and safety of acupoint catgut embedding therapy for depression: a protocol for systematic review and meta-analysis
  8 January 2024 | Frontiers in Psychiatry, Vol. 14
- Post-traumatic stress disorder and neuromodulation methods in treating PTSD
- Escetamina intranasal no manejo da depressão resistente ao tratamento em paciente com história de negligência emocional na infância
  23 April 2024 | Debates em Psiquiatria, Vol. 14
- Ketamine in neuropsychiatric disorders: an update
  20 June 2023 | Neuropsychopharmacology, Vol. 49, No. 1
- The why, when, where, how, and so what of so-called rapidly acting antidepressants
  17 July 2023 | Neuropsychopharmacology, Vol. 49, No. 1
- Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
  24 July 2023 | Neuropsychopharmacology, Vol. 49, No. 1
- Antidepressants enter cells, organelles, and membranes
  2 October 2023 | Neuropsychopharmacology, Vol. 49, No. 1
- A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders
  Journal of Affective Disorders, Vol. 345
- Ketamine and Nitrous Oxide
- Apoptotic mechanism of development inhibition in zebrafish induced by esketamine
  Toxicology and Applied Pharmacology, Vol. 482
- Esketamine inhibits the c-Jun N-terminal kinase pathway in the spinal dorsal horn to relieve bone cancer pain in rats
  13 March 2024 | Molecular Pain, Vol. 20
- Pharmacological treatment of treatment-resistant depression: Towards evidence-based recommendations
  Medicinska istrazivanja, Vol. 57, No. 1
- Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
  1 March 2024 | American Journal of Therapeutics, Vol. 31, No. 2
- Interventional therapeutics in psychiatry: Beyond psychopharmacology and psychotherapy?
- Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans
  22 March 2023 | Journal of Medical Economics, Vol. 26, No. 1
- High-dose Versus Low-dose Oral Ketamine on Control and Relapse of Treatment-resistant Depression: A Randomized, Double-blinded Clinical Trial
  20 December 2023 | Iranian Journal of Psychiatry and Behavioral Sciences, Vol. 17, No. 4
- Anatomy of a Woebot® (WB001): agent guided CBT for women with postpartum depression
  21 November 2023 | Expert Review of Medical Devices, Vol. 20, No. 12
- Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
  8 May 2023 | Health and Quality of Life Outcomes, Vol. 21, No. 1
- Frontoamygdalar Effective Connectivity in Youth Depression and Treatment Response
  Biological Psychiatry, Vol. 94, No. 12
- Establishing an esketamine clinic in Australia: Practical recommendations and clinical guidance from an expert panel
  6 November 2023 | Asia-Pacific Psychiatry, Vol. 15, No. 4
- Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel
  23 November 2023 | Annals of General Psychiatry, Vol. 22, No. 1
- Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
  7 December 2023 | Middle East Current Psychiatry, Vol. 30, No. 1
- The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
  13 December 2023 | Pharmaceutics, Vol. 15, No. 12
- What clinicians need to know about intranasal esketamine for treatment-resistant depression?
  14 November 2023 | Australasian Psychiatry, Vol. 31, No. 6
- Early effects predict trajectories of response to esketamine in treatment-resistant depression
  Journal of Affective Disorders, Vol. 342
- A Pain Physician and Anesthesiologist’s Perspective on Ketamine for Treatment-Resistant Depression
  15 March 2023 | SN Comprehensive Clinical Medicine, Vol. 5, No. 1
- Overcoming the myths of esketamine administration: different and not difficult
  23 November 2023 | Frontiers in Psychiatry, Vol. 14
- Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
  7 November 2023 | Pharmaceuticals, Vol. 16, No. 11
- Ketamine for Traumatic Assault-Induced Depression: A Case Report
  Journal of Trauma Nursing, Vol. 30, No. 6
- Antidepressant mechanisms of ketamine’s action: NF-κB in the spotlight
  Biochemical Pharmacology, Vol. 48
- DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illness
  7 September 2023 | Molecular Psychiatry, Vol. 28, No. 11
- Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study
  31 October 2023 | Frontiers in Psychiatry, Vol. 14
- ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry
  31 October 2023 | Frontiers in Psychiatry, Vol. 14
- Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
  New England Journal of Medicine, Vol. 389, No. 14
- Esmethadone-HCl (REL-1017): a promising rapid antidepressant
  8 March 2023 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 273, No. 7
- Challenges of research on treatment‐resistant depression: a clinician's perspective
  15 September 2023 | World Psychiatry, Vol. 22, No. 3
- Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice?
  21 June 2023 | British Journal of Pain, Vol. 17, No. 5
- The Patient’s Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression
  22 October 2023 | Brain Sciences, Vol. 13, No. 10
- A New Solution to an Age-old Problem: A Review of Ketamine and Esketamine for Treatment-resistant Depression in Late Life
  18 May 2023 | Current Geriatrics Reports, Vol. 12, No. 3
- Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
  Psychiatry Research, Vol. 327
- Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: A case report
  10 August 2023 | Bipolar Disorders, Vol. 25, No. 6
- Influence of low-dose esketamine on postoperative depressive symptoms in patients with breast cancer (EASE): study protocol for a randomised controlled trial
  25 September 2023 | BMJ Open, Vol. 13, No. 9
- Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study
  European Neuropsychopharmacology, Vol. 74
- Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review
  28 August 2023 | Journal of Psychoactive Drugs, Vol. 34
- Comments to Drs Taillefer de Laportalière, Jullien, Yrondi, Cestac, and Montastruc
  23 August 2023 | Psychological Medicine
- Change in Negative Affective Bias following a Single Ketamine Treatment for Treatment-Resistant Depression
  Depression and Anxiety, Vol. 2023
- Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance
  3 August 2023 | Current Medical Research and Opinion, Vol. 39, No. 8
- Commentary on Cochrane review: “Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder”
  11 October 2022 | Journal of Psychopharmacology, Vol. 37, No. 8
- Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder
  14 August 2023 | JAMA Network Open, Vol. 6, No. 8
- Ketamine for the treatment of major depression: a systematic review and meta-analysis
  eClinicalMedicine, Vol. 62
- Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression
  Journal of Affective Disorders, Vol. 334
- Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial
  14 July 2023 | The British Journal of Psychiatry, Vol. 9
- Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder
  11 July 2023 | Frontiers in Neuroscience, Vol. 17
- A systematic review of the print media representation of ketamine treatments for psychiatric disorders
  7 June 2023 | BJPsych Open, Vol. 9, No. 4
- Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
  12 May 2023 | Neuropsychopharmacology, Vol. 48, No. 8
- Clinical use of ketamine in psychiatric disorders
  Annales Médico-psychologiques, revue psychiatrique, Vol. 181, No. 6
- Extended applications the subcutaneous esketamine for major depression with suicidal ideation in autism traits—Case report
  Psychiatry Research Case Reports, Vol. 2, No. 1
- Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study
  Journal of Affective Disorders, Vol. 330
- The antidepressant actions of ketamine and its enantiomers
  Pharmacology & Therapeutics, Vol. 246
- Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression
  12 May 2023 | Pharmaceuticals, Vol. 16, No. 5
- Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression
  18 January 2023 | Bipolar Disorders, Vol. 25, No. 3
- Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency: case presentations
  27 December 2022 | International Clinical Psychopharmacology, Vol. 38, No. 3
- Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray
  Psychiatry Research, Vol. 323
- Reporting of harms in clinical trials of esketamine in depression: a systematic review
  26 April 2023 | Psychological Medicine
- The role and mechanism of tryptophan – kynurenine metabolic pathway in depression
  5 September 2022 | Reviews in the Neurosciences, Vol. 34, No. 3
- Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
  2 February 2023 | Psychopharmacology, Vol. 240, No. 4
- Pharmacologic Approaches to Suicide Prevention
  Sidney Zisook, M.D.,
  Isabel Domingues, M.D.,
  Jason Compton, M.D.
  14 April 2023 | FOCUS, Vol. 21, No. 2
- REPEATED DOSES OF SUBCUTANEOUS ESKETAMINE IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION: CASE SERIES IN A GENERAL HOSPITAL IN SOUTHERN BRAZIL
  Psychiatry Research Case Reports, Vol. 66
- Evaluation of Ethnicity Effect on Intranasal Esketamine Pharmacokinetics by Population Pharmacokinetic Modeling Using Data From a Japanese Phase 2b Study
  22 December 2022 | Clinical Pharmacology in Drug Development, Vol. 12, No. 4
- Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
  16 December 2022 | International Journal of Neuropsychopharmacology, Vol. 26, No. 3
- Ketamine study: Protocol for naturalistic prospective multicenter study on subcutaneous ketamine infusion in depressed patients with active suicidal ideation
  9 March 2023 | Frontiers in Psychiatry, Vol. 14
- Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery
  23 February 2023 | Pharmaceutics, Vol. 15, No. 3
- Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape
  Manish K. Jha, M.B.B.S.,
  Sanjay J. Mathew, M.D.
  1 March 2023 | American Journal of Psychiatry, Vol. 180, No. 3
- Completed suicides and intranasal esketamine therapy: A case report and case series
  Psychiatry Research Case Reports, Vol. 235
- Effects of Cang-Ai volatile oil on depressed mood and cortical excitability in human
  Pharmacological Research - Modern Chinese Medicine, Vol. 6
- Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression
  21 July 2022 | Journal of Psychopharmacology, Vol. 37, No. 3
- Transcranial direct current stimulation for bipolar depression: systematic reviews of clinical evidence and biological underpinnings
  Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 121
- Pharmacotherapy
  Psychiatric Clinics of North America, Vol. 15
- Effects of (S)-ketamine on depression-like behaviors in a chronic variable stress model: a role of brain lipidome
  15 February 2023 | Frontiers in Cellular Neuroscience, Vol. 17
- Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
  20 January 2023 | PharmacoEconomics, Vol. 41, No. 2
- Safety and Tolerability of the Acute Ketamine Treatment in Treatment-Resistant Depression: Focus on Comorbidities Interplay with Dissociation and Psychomimetic Symptoms
  24 January 2023 | Pharmaceuticals, Vol. 16, No. 2
- New and emerging approaches to treat psychiatric disorders
  16 February 2023 | Nature Medicine, Vol. 29, No. 2
- The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
  Neuropharmacology, Vol. 223
- Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites
  Neuropharmacology, Vol. 223
- The effect of low-dose esketamine on pain and post-partum depression after cesarean section: A prospective, randomized, double-blind clinical trial
  4 January 2023 | Frontiers in Psychiatry, Vol. 13
- Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression
  26 December 2022 | Pharmaceuticals, Vol. 16, No. 1
- Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
  1 February 2023 | Neuropsychiatric Disease and Treatment, Vol. Volume 19
- Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability
  Journal of Affective Disorders, Vol. 321
- The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?
  23 March 2023
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA
  1 March 2023 | Neuropsychiatric Disease and Treatment, Vol. Volume 19
- The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis
  1 January 2023 | Revista da Associação Médica Brasileira, Vol. 69, No. 4
- Novel and emerging treatments for major depression
  The Lancet, Vol. 401, No. 10371
- The use of esketamine in the treatment of patients with oral antidepressant-resistant depression: systematic review and meta-analysis
  1 January 2023 | Revista da Associação Médica Brasileira, Vol. 69, No. 6
- The “new wave” of antidepressants: are these agents paradigm-shifters in treating major depression?
  Psihiatru.ro, Vol. 4, No. 75
- A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics
  1 December 2023 | Neuropsychiatric Disease and Treatment, Vol. Volume 19
- Pharmakotherapie: Allgemeine Aspekte
- Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine
  15 July 2022 | Hormone Molecular Biology and Clinical Investigation, Vol. 43, No. 4
- Ketamine treatment for depression: a review
  15 April 2022 | Discover Mental Health, Vol. 2, No. 1
- New treatments for mental disorders should be routinely compared to psychotherapy in trials conducted for regulatory purposes
  The Lancet Psychiatry, Vol. 9, No. 12
- Comparative efficacy, cognitive effects and acceptability of electroconvulsive therapies for the treatment of depression: protocol for a systematic review and network meta-analysis
  22 December 2022 | BMJ Open, Vol. 12, No. 12
- Effect of different doses of esketamine compared with fentanyl combined with propofol on hypotension in patients undergoing painless abortion surgery: a prospective, randomized, double-blind controlled clinical trial
  28 September 2022 | BMC Anesthesiology, Vol. 22, No. 1
- Opioid-reduced anesthesia based on esketamine in gynecological day surgery: a randomized double-blind controlled study
  16 November 2022 | BMC Anesthesiology, Vol. 22, No. 1
- The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review
  Journal of Affective Disorders, Vol. 318
- Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)
  Journal of Affective Disorders, Vol. 319
- Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine
  24 June 2022 | International Journal of Methods in Psychiatric Research, Vol. 31, No. 4
- When Still Water Runs Deep: The Complexities of Clinically Repurposing FDA Approved Therapies
  Clinical Therapeutics, Vol. 44, No. 11
- Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme
  17 February 2022 | International Journal of Psychiatry in Clinical Practice, Vol. 26, No. 4
- Characteristics of Real-world Commercially Insured Patients With Treatment-resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States
  Clinical Therapeutics, Vol. 44, No. 11
- Expectancy in placebo-controlled trials of psychedelics: if so, so what?
  5 September 2022 | Psychopharmacology, Vol. 239, No. 10
- Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression
  31 August 2022 | Clinical Drug Investigation, Vol. 42, No. 10
- Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review
  28 September 2022 | International Journal of Molecular Sciences, Vol. 23, No. 19
- Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
  13 October 2022 | International Journal of Molecular Sciences, Vol. 23, No. 20
- Polypharmacy- Purpose, Benefits and Limitations
  Current Medicinal Chemistry, Vol. 29, No. 35
- Perspective Chapter: NMDA Treatments for CNS Disorders
  14 September 2022
- Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions
  14 September 2022
- Recent Advances in Psychopharmacology
  Advances in Psychiatry and Behavioral Health, Vol. 2, No. 1
- Association of intranasal esketamine, a novel ‘standard of care’ treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice
  1 September 2022 | BMJ Open, Vol. 12, No. 9
- Possible Use of Minocycline in Adjunction to Intranasal Esketamine for the Management of Difficult to Treat Depression following Extensive Pharmacogenomic Testing: Two Case Reports
  16 September 2022 | Journal of Personalized Medicine, Vol. 12, No. 9
- The molecular pathophysiology of depression and the new therapeutics
  21 July 2022 | MedComm, Vol. 3, No. 3
- Psychedelic drugs take on depression
  24 August 2022 | Nature, Vol. 608, No. 7924
- L’efficacité de l’eskétamine dans le trouble dépressif majeur résistant : une revue systématique de la littérature
  L'Encéphale, Vol. 48, No. 4
- Author reply
  18 July 2022 | The British Journal of Psychiatry, Vol. 221, No. 2
- Functional neuroimaging in psychiatry and the case for failing better
  Neuron, Vol. 110, No. 16
- Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
  25 July 2022 | Frontiers in Psychiatry, Vol. 13
- Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder: Open-Label Single-Arm Pilot Study
  8 July 2022 | Frontiers in Psychiatry, Vol. 13
- A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population
  7 June 2022 | Clinical Drug Investigation, Vol. 42, No. 7
- The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry
  Journal of Affective Disorders, Vol. 308
- Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder
  Journal of Affective Disorders, Vol. 308
- Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review
  26 June 2022 | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Vol. 42, No. 7
- РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ
  30 June 2022 | Likarska sprava, No. 3-4
- The Rapid and Long-Lasting Antidepressant Effects of Iridoid Fraction in Gardenia Jasminoides J.Ellis Are Dependent on Activating PKA-CREB Signaling Pathway
  8 June 2022 | Frontiers in Pharmacology, Vol. 13
- Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
  9 March 2022 | Expert Opinion on Drug Safety, Vol. 21, No. 6
- The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis
  6 April 2022 | Expert Opinion on Drug Safety, Vol. 21, No. 6
- Long-term safety of ketamine and esketamine in treatment of depression
  19 April 2022 | Expert Opinion on Drug Safety, Vol. 21, No. 6
- Craving and addictive potential of esketamine as side effects?
  4 May 2022 | Expert Opinion on Drug Safety, Vol. 21, No. 6
- St. Johnʼs wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?
  16 March 2022 | Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 395, No. 6
- Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
  20 April 2022 | CNS Drugs, Vol. 36, No. 6
- Baihe Dihuang (Lilium Henryi Baker and Rehmannia Glutinosa) decoction attenuates somatostatin interneurons deficits in prefrontal cortex of depression via miRNA-144–3p mediated GABA synthesis and release
  Journal of Ethnopharmacology, Vol. 292
- Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti‐depressive drug on the market
  23 December 2021 | Fundamental & Clinical Pharmacology, Vol. 36, No. 3
- Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review
  Psychiatry Research, Vol. 312
- Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study
  The American Journal of Geriatric Psychiatry, Vol. 30, No. 5
- The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
  25 February 2022 | Journal of Psychopharmacology, Vol. 36, No. 5
- The effectiveness of repeated intravenous ketamine on subjective and objective psychosocial function in patients with treatment-resistant depression and suicidal ideation
  Journal of Affective Disorders, Vol. 304
- Is treatment-resistant depression really resistant?
  European Neuropsychopharmacology, Vol. 58
- Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
  12 January 2022 | International Journal of Neuropsychopharmacology, Vol. 25, No. 4
- Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
  8 April 2022 | Frontiers in Pharmacology, Vol. 13
- Anatomy of a Woebot® (WB001): agent guided CBT for women with postpartum depression
  23 June 2022 | Expert Review of Medical Devices, Vol. 19, No. 4
- Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
  1 January 2022 | Archives of Women's Mental Health, Vol. 25, No. 2
- Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
  European Neuropsychopharmacology, Vol. 57
- Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.
  17 February 2022 | Molecular Psychiatry, Vol. 27, No. 4
- Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers
  Biochemical Pharmacology, Vol. 198
- The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
  Cureus, Vol. 175
- Health-related quality of life burden associated with treatment-resistant depression in UK patients: Quantitative results from a mixed-methods non-interventional study
  Journal of Affective Disorders, Vol. 300
- A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings
  Journal of Affective Disorders, Vol. 301
- Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence
  Journal of the Neurological Sciences, Vol. 434
- Suizidpräventive Effekte von Ketamin und Esketamin
  4 April 2022 | Nervenheilkunde, Vol. 41, No. 04
- CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
  Neuropharmacology, Vol. 206
- Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses
  27 October 2021 | European Journal of Clinical Pharmacology, Vol. 78, No. 3
- Beating pain with psychedelics: Matter over mind?
  Neuroscience & Biobehavioral Reviews, Vol. 134
- Research advances in the clinical application of esketamine
  5 March 2022 | Ibrain, Vol. 8, No. 1
- Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression– an Asian Sub-group Analysis from the SUSTAIN-2 Study
  Clinical Psychopharmacology and Neuroscience, Vol. 20, No. 1
- Efficacy and safety of repeated esketamine intravenous infusion in the treatment of treatment-resistant depression: A case series
  Asian Journal of Psychiatry, Vol. 68
- Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study
  1 July 2021 | Expert Opinion on Drug Safety, Vol. 21, No. 1
- Esketamine for treatment-resistant depression in adults
  24 January 2022 | Cochrane Database of Systematic Reviews, Vol. 2022, No. 1
- Translational Neuropsychopharmacology for Major Depression: Targeting Neurotransmitter Systems
  1 January 2022
- Ketamine and Other Glutamate Receptor Antagonists As Fast-Actin
  1 January 2022
- Ketamine in Psychiatric Disorders
  5 November 2022
- The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression
  11 April 2022
- Treatment Resistance and Advanced Therapies
  18 August 2022
- U.S. Food and Drug Administration’s Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant Depression
  8 October 2021 | Therapeutic Innovation & Regulatory Science, Vol. 56, No. 1
- Antidepressant Drugs
- Depression management and pharmacoepigenetics
- Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression
  1 June 2022 | Neuropsychiatric Disease and Treatment, Vol. Volume 18
- Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis
  1 December 2022 | Neuropsychiatric Disease and Treatment, Vol. Volume 18
- “Drugs of Abuse” as “New Antidepressants”: - Medical and Philosophical Considerations in Treatment
  Journal of Korean Neuropsychiatric Association, Vol. 61, No. 4
- Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression - The KADS Study: A Randomised, Double-Blind, Comparator-Controlled Trial
  SSRN Electronic Journal, Vol. 9
- Protocol for the Ketamine for Postoperative Avoidance of Depressive Symptoms (K-PASS) feasibility study: A randomized clinical trial
  11 May 2022 | F1000Research, Vol. 11
- Depression and Anxiety Disorders
  17 December 2021
- Suppressed activity of the rostral anterior cingulate cortex as a biomarker for depression remission
  9 December 2021 | Psychological Medicine, Vol. 11
- P.0366 Sleep disturbance and efficacy of esketamine nasal spray in patients with treatment-resistant depression: findings from randomized, controlled trials
  European Neuropsychopharmacology, Vol. 53
- P.0391 Ultra-resistant major depression: treatment with in-esketamine on compassionate use
  European Neuropsychopharmacology, Vol. 53
- The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality
  Journal of Psychiatric Research, Vol. 144
- Recent advances and challenges in major depressive disorder
  Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 111
- Ketamine treatment for depression: A model of care
  13 August 2021 | Australian & New Zealand Journal of Psychiatry, Vol. 55, No. 12
- Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study
  25 October 2021 | BMC Psychiatry, Vol. 21, No. 1
- Research progress of non-monoamine antidepressants
  Stress and Brain, Vol. 1, No. 2
- Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review
  2 December 2021 | International Journal of Molecular Sciences, Vol. 22, No. 23
- Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder
  5 August 2021 | Translational Psychiatry, Vol. 11, No. 1
- Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder
  12 September 2021 | Cochrane Database of Systematic Reviews, Vol. 2021, No. 11
- The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
  22 July 2021 | Depression and Anxiety, Vol. 38, No. 11
- Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: Results from the Canadian Rapid Treatment Centre of Excellence
  Journal of Psychiatric Research, Vol. 143
- A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants
  Progress in Neurobiology, Vol. 206
- Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review
  5 November 2021 | Life, Vol. 11, No. 11
- Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease
  Pharmacology & Therapeutics, Vol. 227
- A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice
  12 October 2021 | Frontiers in Human Neuroscience, Vol. 15
- Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior
  Biological Psychiatry, Vol. 90, No. 7
- The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression
  Revista de Psiquiatría y Salud Mental, Vol. 14, No. 4
- The probability of response after each subcutaneous injection of esketamine in treatment-resistant depression
  Revista de Psiquiatría y Salud Mental (English Edition), Vol. 14, No. 4
- Targeting the dysfunction of glutamate receptors for the development of novel antidepressants
  Pharmacology & Therapeutics, Vol. 226
- Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review
  Journal of Affective Disorders, Vol. 293
- Ketamine in depression and electroconvulsive therapy
  22 July 2021 | Current Opinion in Anaesthesiology, Vol. 34, No. 5
- An update on antidepressant pharmacotherapy in late-life depression
  19 June 2021 | Expert Opinion on Pharmacotherapy, Vol. 22, No. 14
- Blinding and expectancy confounds in psychedelic randomized controlled trials
  26 August 2021 | Expert Review of Clinical Pharmacology, Vol. 14, No. 9
- Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders
  7 August 2021 | CNS Drugs, Vol. 35, No. 9
- Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
  20 August 2021 | Journal of Clinical Psychopharmacology, Vol. 41, No. 5
- Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review
  28 August 2021 | International Journal of Molecular Sciences, Vol. 22, No. 17
- Role of the Pharmacist in Managing Treatment-Resistant Depression: A Focus on Ketamine
  25 June 2021 | Pharmacy, Vol. 9, No. 3
- Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study
  Psychiatry Research, Vol. 303
- Novel Antidepressant Approaches for Refractory Depression
  30 July 2021 | Current Treatment Options in Psychiatry, Vol. 8, No. 3
- Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review
  Cureus, Vol. 15
- A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough?
  8 December 2020 | The World Journal of Biological Psychiatry, Vol. 22, No. 7
- Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study
  20 July 2021 | CNS Drugs, Vol. 35, No. 8
- Fluoroethylnormemantine, A Novel Derivative of Memantine, Facilitates Extinction Learning Without Sensorimotor Deficits
  25 February 2021 | International Journal of Neuropsychopharmacology, Vol. 24, No. 6
- Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance
  12 November 2020 | The World Journal of Biological Psychiatry, Vol. 22, No. 6
- Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
  7 July 2021 | CNS Drugs, Vol. 35, No. 7
- Spravato oder die Frage: „Wie viel darf ein Antidepressivum kosten?“
  14 July 2021 | Psychiatrische Praxis, Vol. 48, No. 05
- Intranasal esketamine use in bipolar disorder: A case report
  16 July 2021 | Mental Health Clinician, Vol. 11, No. 4
- Translating Interventional Neuroscience to Suicide: It’s About Time
  Biological Psychiatry, Vol. 89, No. 11
- Trait dissociation as a predictor of induced dissociation by ketamine or esketamine in treatment-resistant depression: Secondary analysis from a randomized controlled trial
  Journal of Psychiatric Research, Vol. 138
- Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
  4 February 2021 | Translational Psychiatry, Vol. 11, No. 1
- Intranasal Ketamine for Depression in Adults: A Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
  1 June 2021 | Frontiers in Psychology, Vol. 12
- Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications
  13 February 2021 | Neuroscience Bulletin, Vol. 37, No. 6
- New drugs in psychiatry - cariprazine, lurasidone, esketamine
  23 November 2021 | Current Problems of Psychiatry, Vol. 22, No. 2
- Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
  Clinical Psychopharmacology and Neuroscience, Vol. 19, No. 2
- Subcutaneous Ketamine in Depression: A Systematic Review
  28 May 2021 | Frontiers in Psychiatry, Vol. 12
- Repeated Dosing of Ketamine in the Forced Swim Test: Are Multiple Shots Better Than One?
  11 May 2021 | Frontiers in Psychiatry, Vol. 12
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
  Roger S. McIntyre, M.D.,
  Joshua D. Rosenblat, M.D., M.Sc.,
  Charles B. Nemeroff, M.D., Ph.D.,
  Gerard Sanacora, M.D., Ph.D.,
  James W. Murrough, M.D., Ph.D.,
  Michael Berk, Ph.D., M.B.B.Ch.,
  Elisa Brietzke, M.D., Ph.D.,
  Seetal Dodd, Ph.D.,
  Philip Gorwood, M.D., Ph.D.,
  Roger Ho, M.D., M.B.B.S.,
  Dan V. Iosifescu, M.D.,
  Carlos Lopez Jaramillo, M.D., Ph.D.,
  Siegfried Kasper, M.D.,
  Kevin Kratiuk, B.Pharm.,
  Jung Goo Lee, M.D., Ph.D.,
  Yena Lee, H.B.Sc.,
  Leanna M.W. Lui,
  Rodrigo B. Mansur, M.D., Ph.D.,
  George I. Papakostas, M.D.,
  Mehala Subramaniapillai, M.Sc.,
  Michael Thase, M.D.,
  Eduard Vieta, M.D., Ph.D.,
  Allan H. Young, M.Phil., M.B.Ch.B.,
  Carlos A. ZarateJr., M.D.,
  Stephen Stahl, M.D., Ph.D.
  17 March 2021 | American Journal of Psychiatry, Vol. 178, No. 5
- Scientific Advances Supporting New and Improved Treatment Strategies in Psychiatry
  Ned H. Kalin, M.D.
  12 May 2021 | American Journal of Psychiatry, Vol. 178, No. 5
- Intranasal esketamine: From origins to future implications in treatment-resistant depression
  Journal of Psychiatric Research, Vol. 137
- The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review
  Journal of Psychiatric Research, Vol. 137
- Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
  30 April 2021 | Frontiers in Neuroscience, Vol. 15
- Ketamine for depression
  11 February 2021 | International Review of Psychiatry, Vol. 33, No. 3
- Psilocybin and MDMA for the treatment of trauma-related psychopathology
  14 June 2021 | International Review of Psychiatry, Vol. 33, No. 3
- Esketamine: a glimmer of hope in treatment-resistant depression
  19 November 2019 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 271, No. 3
- Intravenous arketamine for treatment-resistant depression: open-label pilot study
  20 February 2020 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 271, No. 3
- Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression
  Journal of Comparative Effectiveness Research, Vol. 10, No. 5
- 19th Latest Advances in Psychiatry International Symposium
  14 May 2021 | Progress in Neurology and Psychiatry, Vol. 25, No. 2
- Corticotropin Releasing Hormone Signaling in the Bed Nuclei of the Stria Terminalis as a Link to Maladaptive Behaviors
  19 March 2021 | Frontiers in Neuroscience, Vol. 15
- Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics
  Journal of Affective Disorders, Vol. 283
- A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions
  Journal of Affective Disorders, Vol. 282
- Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression
  16 March 2021 | Medicina, Vol. 57, No. 3
- Clinically meaningful changes on depressive symptom measures and patient‐reported outcomes in patients with treatment‐resistant depression
  22 January 2021 | Acta Psychiatrica Scandinavica, Vol. 143, No. 3
- Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property
  26 February 2021 | Frontiers in Pharmacology, Vol. 12
- Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms
  20 February 2021 | Pharmacological Reports, Vol. 28
- Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant
  Journal of Affective Disorders, Vol. 281
- A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom
  25 January 2021 | Current Medical Research and Opinion, Vol. 37, No. 2
- Comparative efficacy and side-effect profile of ketamine and esketamine in the treatment of unipolar and bipolar depression: protocol for a systematic review and network meta-analysis
  12 February 2021 | BMJ Open, Vol. 11, No. 2
- Ketamine: A tale of two enantiomers
  6 November 2020 | Journal of Psychopharmacology, Vol. 35, No. 2
- Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity
  9 January 2021 | Journal of Psychopharmacology, Vol. 35, No. 2
- Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
  13 October 2020 | Clinical Pharmacology & Therapeutics, Vol. 109, No. 2
- Esketamin
  pharma-kritik, Vol. 42, No. 5
- Addiction of Hallucinogens, Dissociatives, Designer Drugs and “Legal Highs”: Update on Potential Therapeutic Use
  4 November 2020
- Therapeutic Use of Hallucinogens
  1 May 2021
- Ketamine in Psychiatric Disorders
  10 June 2021
- Increased use of ketamine for the treatment of depression: Benefits and concerns
  Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 104
- Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research
  17 August 2020 | Molecular Psychiatry, Vol. 26, No. 1
- Les propriétés antidépressives de la kétamine
  25 January 2021 | médecine/sciences, Vol. 37, No. 1
- Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
  27 August 2020 | Psychotherapy and Psychosomatics, Vol. 90, No. 1
- The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
  22 December 2020 | Australian & New Zealand Journal of Psychiatry, Vol. 55, No. 1
- Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression
  19 May 2021 | Therapeutic Advances in Psychopharmacology, Vol. 11
- Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders
  2 June 2021 | Chronic Stress, Vol. 5
- Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
  1 November 2021 | Neuropsychiatric Disease and Treatment, Vol. Volume 17
- Ketamine for treatment-resistant depression
  Mustansiriya Medical Journal, Vol. 20, No. 2
- “Novel Psychopharmacology for Depressive Disorders”
  9 April 2021
- Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study
  23 July 2021 | Medicine, Vol. 100, No. 29
- Managing dissociative symptoms following the use of esketamine nasal spray: a case report
  13 August 2020 | International Clinical Psychopharmacology, Vol. 36, No. 1
- Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials
  1 March 2021 | Journal of Psychiatric Practice, Vol. 27, No. 2
- Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
  Journal of Affective Disorders, Vol. 278
- Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
  5 May 2020 | International Journal of Neuropsychopharmacology, Vol. 23, No. 9
- A Virtual Standardized Patient–Based Assessment Tool to Evaluate Psychiatric Residents’ Psychopharmacology Proficiency
  17 July 2020 | Academic Psychiatry, Vol. 44, No. 6
- Psychotropes du futur : de l’imipramine à la kétamine
  Bulletin de l'Académie Nationale de Médecine, Vol. 204, No. 9
- Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression
  Journal of Affective Disorders, Vol. 277
- A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
  Trends in Neurosciences, Vol. 47
- Mechanisms associated with the antidepressant-like effects of L-655,708
  20 July 2020 | Neuropsychopharmacology, Vol. 45, No. 13
- A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression
  26 June 2020 | Translational Psychiatry, Vol. 10, No. 1
- The role of dissociation in ketamine’s antidepressant effects
  22 December 2020 | Nature Communications, Vol. 11, No. 1
- Genome-wide association study and polygenic risk score analysis of esketamine treatment response
  28 July 2020 | Scientific Reports, Vol. 10, No. 1
- Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets
  3 November 2020 | Expert Opinion on Therapeutic Targets, Vol. 24, No. 12
- Esketamine for treatment-resistant depression
  26 November 2020 | Drug and Therapeutics Bulletin, Vol. 58, No. 12
- Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
  26 February 2020 | Annals of General Psychiatry, Vol. 19, No. 1
- Treatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort
  10 December 2020 | Brain Sciences, Vol. 10, No. 12
- Repurposing of Drugs–The Ketamine Story
  11 September 2020 | Journal of Medicinal Chemistry, Vol. 63, No. 22
- Prescriber's Guide
  19 October 2021 | , Vol. 60
- Esketamine
- P.263 Outcome of treatment in clinical practice compared to a clinical trial in treatment-resistant depression: a matched adjusted indirect comparison
  European Neuropsychopharmacology, Vol. 40
- Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions
  26 October 2020 | International Journal of Molecular Sciences, Vol. 21, No. 21
- Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study
  7 August 2020 | International Clinical Psychopharmacology, Vol. 35, No. 6
- Developments in the discovery and design of intranasal antidepressants
  21 June 2020 | Expert Opinion on Drug Discovery, Vol. 15, No. 10
- Is Testosterone an Effective Hormonal Therapy for Women With Antidepressant-Resistant Major Depression?
  Sanjay J. Mathew, M.D.
  1 October 2020 | American Journal of Psychiatry, Vol. 177, No. 10
- Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States
  Eric L. Ross, M.D., and
  Djøra I. Soeteman, Ph.D.
  7 July 2020 | Psychiatric Services, Vol. 71, No. 10
- Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis
  7 March 2020 | Psychiatric Quarterly, Vol. 91, No. 3
- Patient preferences for ketamine-based antidepressant treatments in treatment-resistant depression: Results from a clinical trial and panel
  Neurology, Psychiatry and Brain Research, Vol. 37
- Fairness and Protection for the Vulnerable: Lessons from Esketamine
  25 August 2020 | The American Journal of Bioethics, Vol. 20, No. 9
- Intranasal esketamine: A novel drug for treatment-resistant depression
  30 July 2020 | American Journal of Health-System Pharmacy, Vol. 77, No. 17
- Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review
  Behavioural Brain Research, Vol. 392
- AMBMP activates WNT pathway and alleviates stress-induced behaviors in maternal separation and chronic stress models
  European Journal of Pharmacology, Vol. 881
- Recovery from recurrent depression: Randomized controlled trial of the efficacy of mindfulness-based compassionate living compared with treatment-as-usual on depressive symptoms and its consolidation at longer term follow-up
  Journal of Affective Disorders, Vol. 273
- Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
  9 April 2020 | International Journal of Neuropsychopharmacology, Vol. 23, No. 7
- Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression
  8 July 2020 | Journal of Psychopharmacology
- Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats
  7 April 2020 | Journal of Pharmacology and Experimental Therapeutics, Vol. 374, No. 1
- Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials
  16 April 2020 | Pharmacological Reports, Vol. 72, No. 3
- Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed
  Journal of Affective Disorders, Vol. 271
- Safety and efficacy of esketamine nasal spray in a depressed patient who was being treated with tranylcypromine: A case report
  Neurology, Psychiatry and Brain Research, Vol. 36
- Esketamine: A Novel Option for Treatment-Resistant Depression
  4 December 2019 | Annals of Pharmacotherapy, Vol. 54, No. 6
- Pharmacological Treatments for Patients with Treatment-Resistant Depression
  4 June 2020 | Pharmaceuticals, Vol. 13, No. 6
- Are we repeating mistakes of the past? A review of the evidence for esketamine
  27 May 2020 | The British Journal of Psychiatry, Vol. 2
- Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents
  Journal of the Neurological Sciences, Vol. 412
- Rapid anti‐depressant‐like effects of ketamine and other candidates: Molecular and cellular mechanisms
  7 April 2020 | Cell Proliferation, Vol. 53, No. 5
- An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
  Current Topics in Medicinal Chemistry, Vol. 20, No. 7
- Ketamine: Leading us into the future for development of antidepressants
  Behavioural Brain Research, Vol. 383
- A New Rapid-Acting Antidepressant
  Cell, Vol. 181, No. 1
- The identification, assessment and management of difficult-to-treat depression: An international consensus statement
  Journal of Affective Disorders, Vol. 267
- Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
  Psychiatry Investigation, Vol. 17, No. 3
- Approval of esketamine for treatment-resistant depression
  The Lancet Psychiatry, Vol. 7, No. 3
- Approval of esketamine for treatment-resistant depression – Authors' reply
  The Lancet Psychiatry, Vol. 7, No. 3
- The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review
  Journal of Affective Disorders, Vol. 264
- Part I: Optimizing treatment with antidepressants
  9 March 2020 | JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Vol. 3, No. 2
- Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies
  Journal of Affective Disorders, Vol. 265
- Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression
  Journal of Affective Disorders, Vol. 263
- Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression—TRANSFORM-3
  The American Journal of Geriatric Psychiatry, Vol. 28, No. 2
- Emerging concepts on the use of ketamine for chronic pain
  28 January 2020 | Expert Review of Clinical Pharmacology, Vol. 13, No. 2
- Development of Ketamine Administration as a Treatment for Chronic PTSD
  Psychiatric Annals, Vol. 50, No. 2
- Comparative Efficacy of Ketamine in Treatment-Resistant Depression
  Psychiatric Annals, Vol. 50, No. 2
- Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder
  30 October 2019 | Expert Opinion on Pharmacotherapy, Vol. 21, No. 1
- Glutamine and New Pharmacological Targets to Treat Suicidal Ideation
  15 September 2020
- Ketamine for depression clinical issues
- Antidepressant mechanisms of ketamine: Focus on GABAergic inhibition
- Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence
- Clinical overview of NMDA-R antagonists and clinical practice
- Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants
- The emergence of ketamine as a novel treatment for posttraumatic stress disorder
- Esketamina intranasal: un nuevo abordaje para el tratamiento de la depresión resistente al tratamiento
  Psiquiatría Biológica, Vol. 27, No. 1
- Tratamientos disruptivos en psiquiatría
  Revista de Psiquiatría y Salud Mental, Vol. 13, No. 1
- Disruptive treatments in psychiatry
  Revista de Psiquiatría y Salud Mental (English Edition), Vol. 13, No. 1
- Esketamine for treatment resistant depression: a trick of smoke and mirrors?
  16 December 2019 | Epidemiology and Psychiatric Sciences, Vol. 29
- Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
  29 April 2020 | Epidemiology and Psychiatric Sciences, Vol. 29
- Esketamine clinical trials: reply to Maju et al.
  29 April 2020 | Epidemiology and Psychiatric Sciences, Vol. 29
- Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review
  23 July 2020 | Therapeutic Advances in Drug Safety, Vol. 11
- Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
  11 May 2020 | Therapeutic Advances in Psychopharmacology, Vol. 10
- Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression
  23 December 2020 | Therapeutic Advances in Psychopharmacology, Vol. 10
- The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression
  Journal of Managed Care & Specialty Pharmacy, Vol. 26, No. 1
- <p>Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia</p>
  1 December 2020 | Neuropsychiatric Disease and Treatment, Vol. Volume 16
- <p>Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression</p>
  1 October 2020 | Neuropsychiatric Disease and Treatment, Vol. Volume 16
- New Somatic Treatments for Child and Adolescent Depression
  12 November 2019 | Current Treatment Options in Psychiatry, Vol. 6, No. 4
- Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
  The Lancet Psychiatry, Vol. 6, No. 12
- Intranasal esketamine in treatment-resistant depression: a profile of its use
  28 September 2019 | Drugs & Therapy Perspectives, Vol. 35, No. 11
- Comment on a Word to the Wise About Intranasal Esketamine
  Wayne C. Drevets, M.D.,
  Jaskaran B. Singh, M.D.,
  David Hough, M.D.,
  Ella J. Daly, M.D.,
  Vanina Popova, M.D.,
  Husseini Manji, M.D.
  1 October 2019 | American Journal of Psychiatry, Vol. 176, No. 10
- More Thoughts on Intranasal Esketamine: Response to Drevets et al.
  Alan F. Schatzberg, M.D.
  1 October 2019 | American Journal of Psychiatry, Vol. 176, No. 10
- Neue Erkenntnisse aus der Depressionsforschung
  30 September 2019 | DNP - Der Neurologe & Psychiater, Vol. 20, No. 5
- Developing Novel Psychopharmacological Strategies and Therapeutics
  Ned H. Kalin, M.D.
  1 June 2019 | American Journal of Psychiatry, Vol. 176, No. 6
- A Word to the Wise About Intranasal Esketamine
  Alan F. Schatzberg, M.D.
  21 May 2019 | American Journal of Psychiatry, Vol. 176, No. 6
- Expert Review of Neurotherapeutics, Vol. 19, No. 10
- Expert Review of Neurotherapeutics, Vol. 19, No. 11
- BMJ

Volume 176
Issue 6

June 01, 2019
Pages 428-438

Featured in our Alexa Flash Briefing, Psychiatric News Brief.

Metrics

Keywords

The authors acknowledge Sandra Norris, Pharm.D., of the Norris Communications Group, for medical writing assistance and Ellen Baum, Ph.D., of Janssen Global Services, for additional editorial support. The authors also thank the study patients and the investigators (listed in online supplement) for their participation in this study.

History

Received 15 February 2019

Revised 13 March 2019

Accepted 28 March 2019

Published online 21 May 2019

Published in print 1 June 2019